Composer · investment strategy
by Composer Technologies · via Composer
Buys an equal-weight basket of companies that led in patent approvals during 2010–2017—an easy-to-understand bet on innovation intensity. Tech- and semiconductor-heavy with some industrial, consumer, and healthcare names; includes several foreign ADRs.
Description from Composer
of the return and risk figures:as the source publishes them
What $10,000 would have become, from the strategy's own published history, against the S&P 500 over the same dates. The basis is labelled.
This strategy doesn’t publish a performance history we can chart.
Each rule is quoted word for word from the strategy's own documents.
No rules extracted from this strategy’s text yet.
25 positions as of 2026-10-11
: the platform's backtest holdings, not a client account.
Compares the stated rules with the holdings (or, where none are published, a mix estimated from returns), using tests fixed before any results were seen.
4.2% of weight in (IVV: 3.0%)
No funds
This strategy’s rules haven’t been extracted yet, so there’s no claim to compare with. The measurement is still shown. : 100% · 2026-10-11 ()
0.0% of weight in (SPY: 0%)
This strategy’s rules haven’t been extracted yet, so there’s no claim to compare with. The measurement is still shown. : 100% · 2026-10-11 ()
0 of 24 funds in its are
This strategy’s rules haven’t been extracted yet, so there’s no claim to compare with. The measurement is still shown. : 100%
Strategies that share its Thematic label, from other sources first, strongest risk-adjusted return first.
Interactive Advisors
How much of what we look for this strategy has, and why anything is missing. Fields that don't apply to it aren't counted.
4 missing
The text the rules are quoted from, with where it came from.
Each quarter, buy equal amounts of ~25 companies that ranked highest for patents granted in 2010–2017 (using yearly percentiles to smooth rule changes).<br>Tilt: chipmakers and big tech (AAPL, MSFT, IBM, INTC, TSM—tickers are stock symbols), plus industrials (GE, BA), consumer (NKE, PG), healthcare (MDT), energy (BKR), and several foreign ADRs (SONY, SAP, HMC).
Buys an equal-weight basket of companies that led in patent approvals during 2010–2017—an easy-to-understand bet on innovation intensity. Tech- and semiconductor-heavy with some industrial, consumer, and healthcare names; includes several foreign ADRs.
Patents-led, equal-weight tech portfolio targets higher upside: ~17.6% OOS annualized return vs SPY’s ~14.7%, with positive alpha and solid risk-adjusted gains. Global exposure; quarterly rebalance. Note higher drawdowns in tech cycles.
This strategy finds the top 25 companies by average yearly percentile for the number of patents approvals from 2010 to 2017 to normalize for any regulatory changes over the time period. This strategy is rebalanced quarterly. <br><br>To explore our datasets and more strategies, check us out at QuiverQuant.com.
Every value on file, each labelled with its calculation basis and as-of date.
| Backtest final value (from $10,000) | $117k | 2026-10-11 | |
| Backtest regulatory fees | $5 | 2026-10-11 | |
| Backtest slippage cost | $30 | 2026-10-11 |
| AI categories (Composer) | equal-weight, equities, global adrs, innovation/patents, quarterly rebalance, tech-heavy | 2026-10-11 | |
| Asset classes / instruments | equities | 2026-10-11 |
| Logic complexity (node count) | 26 | 2026-10-11 | |
| Rebalance frequency | quarterly | 2026-10-11 |
| Concentration (Herfindahl index, out-of-sample, as Composer reports it) | 0.04 | 2026-10-11 | |
| Ticker universe (assets the logic can hold) | show[ "AAPL", "AMAT", "AVGO", "BA", "BKR", "GE", "HMC", "HON", "IBM", "INTC", "LPL", "LPLA", "MDT", "MSFT", "MU", "NKE", "ORCL", "PG", "QCOM", "SAP", "SONY", "TSM", "TXN", "XRX" ] | 2026-10-11 |
| Alpha vs SPY, out-of-sample (out-of-sample) | 0.01 | 2026-10-11 | |
| Beta vs SPY, out-of-sample (out-of-sample) | 1.14 | 2026-10-11 | |
| Correlation (R) vs SPY, out-of-sample (out-of-sample) | 0.91 | 2026-10-11 |
| Remixes (copies) | 109 | 2026-10-11 | |
| Watchers | 173 | 2026-10-11 |
| Backtest length | 3,995 | 2026-10-11 | |
| Out-of-sample length | 1,167 | 2026-10-11 | |
| Return, backtest period (annualized) (backtest) | 16.81% | 2026-10-11 | |
| Return, backtest period (cumulative) (backtest) | 1074% | 2026-10-11 | |
| Return, out-of-sample period (annualized) (out-of-sample) | 17.58% | 2026-10-11 | |
| Return, out-of-sample period (cumulative) (out-of-sample) | 111.81% | 2026-10-11 | |
| Return, trailing 1 day (out-of-sample) | 0.19% | 2026-10-11 | |
| Return, trailing 1 month (out-of-sample) | -1.33% | 2026-10-11 | |
| Return, trailing 1 week (out-of-sample) | -1.04% | 2026-10-11 | |
| Return, trailing 1 year (backtest) | 23.54% | 2026-10-11 | |
| Return, trailing 1 year (out-of-sample) | 23.54% | 2026-10-11 | |
| Return, trailing 2 weeks (out-of-sample) | -1.88% | 2026-10-11 | |
| Return, trailing 3 months (out-of-sample) | -0.32% | 2026-10-11 | |
| SPY annualized return over the backtest window (backtest) | 14.53% | 2026-10-11 |
| Calmar ratio, backtest period (backtest) | 0.45 | 2026-10-11 | |
| Calmar ratio, out-of-sample period (out-of-sample) | 0.60 | 2026-10-11 | |
| Maximum drawdown, backtest period (backtest) | -37.34% | 2026-10-11 | |
| Maximum drawdown, out-of-sample period (out-of-sample) | -29.46% | 2026-10-11 | |
| Sharpe ratio, backtest period (backtest) | 0.86 | 2026-10-11 | |
| Sharpe ratio, out-of-sample period (out-of-sample) | 0.86 | 2026-10-11 | |
| Sortino ratio, backtest period (backtest) | 1.23 | 2026-10-11 | |
| Sortino ratio, out-of-sample period (out-of-sample) | 1.26 | 2026-10-11 | |
| Standard deviation, backtest period (backtest) | 20.51% | 2026-10-11 | |
| Standard deviation, out-of-sample period (out-of-sample) | 21.64% | 2026-10-11 |
| Risk rating (Composer data field) | Aggressive | 2026-10-11 |
| Annualized turnover, backtest period (backtest) | 1.54 | 2026-10-11 | |
| Annualized turnover, out-of-sample period (out-of-sample) | 1.92 | 2026-10-11 | |
| Daily win rate, backtest period (backtest) | 54.62% | 2026-10-11 | |
| Daily win rate, out-of-sample period (out-of-sample) | 54.07% | 2026-10-11 |
Collective2
Composer Technologies · Composer
